Adeline Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 84.00 Cr
- Revenue Growth 20.16%
- Profit Growth 82.45%
- Ebitda 35.07%
- Net Worth 21.66%
- Total Assets 10.67%
About Adeline Pharma
Company Details
-
Location
Rangareddy, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24200TS2016PTC172691
-
Company No.
215615
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 May 2016
-
Date of AGM
06 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Adeline Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Desmond Gomes
|
Managing Director | 03-May-2016 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Arvind Venkat
|
Nominee Director | 24-Jun-2016 | Current |
|
Pearl Gomes
|
Director | 03-May-2016 | Current |
Financial Performance of Adeline Pharma.
Adeline Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.16% increase. The company also saw a substantial improvement in profitability, with a 82.45% increase in profit. The company's net worth Soared by an impressive increase of 21.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adeline Pharma?
In 2022, Adeline Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Keimed Private LimitedArvind Venkat is a mutual person
-
Neelkanth Drugs Private LimitedArvind Venkat is a mutual person
-
Auspharma Private LimitedArvind Venkat is a mutual person
-
Prime Time Logistics Technologies Private Limited
Arvind Venkat is a mutual person
-
Adeline Pharmaceuticals Private Limited
Pearl Gomes and Desmond Gomes are mutual person
Charges (Loans)
₹0
₹84.00 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 56.00 Cr
- Others : 28.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Mar 2021 | Hdfc Bank Limited | ₹33.00 Cr | Satisfied |
| 08 Feb 2019 | Others | ₹28.00 Cr | Satisfied |
| 27 Jun 2016 | Hdfc Bank Limited | ₹23.00 Cr | Satisfied |
How Many Employees Work at Adeline Pharma?
Adeline Pharma has a workforce of 52 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adeline Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adeline Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.